[Esophageal Cancer].
Das Ösophaguskarzinom.
Adenocarcinoma
Dysphagia
Esophageal cancer
Esophagus
Squamous cell carcinoma
Journal
Wiener medizinische Wochenschrift (1946)
ISSN: 1563-258X
Titre abrégé: Wien Med Wochenschr
Pays: Austria
ID NLM: 8708475
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
24
01
2022
accepted:
05
09
2022
medline:
1
6
2023
pubmed:
2
11
2022
entrez:
1
11
2022
Statut:
ppublish
Résumé
Esophageal cancer has poor prognosis and high letality. With yearly 600,000 new cases worldwide it ist he sixt most common cancer worldwide and the eight most deadly. Squamous cell carcinoma is more common in Africa and Asia, whereas incidence of adenocarcinoma ist increasing in Norh America and Europe. Riskfactors include alcohol, smoking, obesity, esophageal stenosis or achalasia. Currently there are no recommendations for prevention strategies or cancer screening. Symptoms in early stages are unspecific, so diagnosis is made late. Diagnostics include gastroscopy, CT, PET and endosonography. Therapeutic approaches are depending on disease stage and patients general condition. In early stages endoscopic resection is the treatment of choice. In higher stages theraoy consists of surgical resection and radiochemotherapy. Generalised stade ist treated with palliative systemic therapy and local interventions. Das Ösophaguskarzinom ist ein Tumor mit schlechter Prognose und hoher Letalität. Mit weltweit jährlich über 600,000 neuen Fällen ist es die sechsthäufigste Neoplasie und die achthäufigste zum Tode führende Krebsart. Das Plattenepithelkarzinom stellt die häufigste Entität in Afrika und Asien dar, wohingegen das Adenokarzinom in Nordamerika und Europa an Häufigkeit zunimmt. Risikofaktoren schließen den Genuss von Alkohol und Tabakwaren, Reflux, Übergewicht, Stenosierungen des Ösophagus und die Achalasie ein. Möglichkeiten der medikamentösen Prophylaxe bestehen ebenso wenig, wie effektive Vorsorgeuntersuchungen. Die Klinik ist im Frühstadium unspezifisch, weshalb die Diagnose meist in späteren Stadien gestellt wird. Diagnostisch kommen Gastroskopie, CT, PET und Endosonographie zum Einsatz. Die Therapie erfolgt abhängig vom Erkrankungsstadium und Allgemeinzustand der betroffenen Patienten. Sie besteht in frühen Stadien aus der endoskopischen oder chirurgischen Resektion, in höheren Stadien in Kombination mit Radio- oder Chemotherapie. Im generalisierten Stadium kommen palliative systemische Therapien in Verbindung mit lokalen Maßnahmen zum Einsatz.
Autres résumés
Type: Publisher
(ger)
Das Ösophaguskarzinom ist ein Tumor mit schlechter Prognose und hoher Letalität. Mit weltweit jährlich über 600,000 neuen Fällen ist es die sechsthäufigste Neoplasie und die achthäufigste zum Tode führende Krebsart. Das Plattenepithelkarzinom stellt die häufigste Entität in Afrika und Asien dar, wohingegen das Adenokarzinom in Nordamerika und Europa an Häufigkeit zunimmt. Risikofaktoren schließen den Genuss von Alkohol und Tabakwaren, Reflux, Übergewicht, Stenosierungen des Ösophagus und die Achalasie ein. Möglichkeiten der medikamentösen Prophylaxe bestehen ebenso wenig, wie effektive Vorsorgeuntersuchungen. Die Klinik ist im Frühstadium unspezifisch, weshalb die Diagnose meist in späteren Stadien gestellt wird. Diagnostisch kommen Gastroskopie, CT, PET und Endosonographie zum Einsatz. Die Therapie erfolgt abhängig vom Erkrankungsstadium und Allgemeinzustand der betroffenen Patienten. Sie besteht in frühen Stadien aus der endoskopischen oder chirurgischen Resektion, in höheren Stadien in Kombination mit Radio- oder Chemotherapie. Im generalisierten Stadium kommen palliative systemische Therapien in Verbindung mit lokalen Maßnahmen zum Einsatz.
Identifiants
pubmed: 36318394
doi: 10.1007/s10354-022-00972-9
pii: 10.1007/s10354-022-00972-9
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
209-215Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, ein Teil von Springer Nature.
Références
6‑Oesophagus-fact-sheet.pdf [Internet]. [zitiert 3. August 2021]. Verfügbar unter: https://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf
Speiseröhre [Internet]. [zitiert 14. September 2021]. Verfügbar unter: http://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/krebserkrankungen/speiseroehre/index.html
Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet Lond Engl. 2. Februar. 2013;381(9864):400–12.
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 4. Dezember 2003;349(23):2241–52.
Pakzad R, Mohammadian-Hafshejani A, Khosravi B, Soltani S, Pakzad I, Mohammadian M, et al. The incidence and mortality of esophageal cancer and their relationship to development in Asia. Ann Transl Med. 2016;4(2):29.
pubmed: 26889482
pmcid: 4731602
Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103(11):2694–9.
doi: 10.1111/j.1572-0241.2008.02191.x
pubmed: 18853967
Global Cancer Facts. Verfügbar unter.. https://www.cancer.org/research/cancer-facts-statistics/global.html . Zugegriffen: 3. Aug. 2021.
Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 1. September 2009;101(5):855–9.
Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol WJG. 14. Juli 2015;21(26):7933–43.
Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, u. a. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 15. Juni 2007;165(12):1424–33.
Zendehdel K, Nyrén O, Edberg A, Ye W. Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol. 2011;106(1):57–61.
doi: 10.1038/ajg.2010.449
pubmed: 21212754
Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012;92(5):1077–87.
doi: 10.1016/j.suc.2012.07.008
pubmed: 23026270
Rubenstein JH, Meta-analysis TJB. the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2010;32(10):1222–7.
doi: 10.1111/j.1365-2036.2010.04471.x
pubmed: 20955441
pmcid: 3481544
Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(3):609–17.
doi: 10.1093/annonc/mds244
Nguyen T, Thrift AP, Yu X, Duan Z, El-Serag HB. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett’s Esophagus. Am J Gastroenterol. 2017;112(7):1049–55.
doi: 10.1038/ajg.2017.18
pubmed: 28244499
Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 13. Oktober 2011;365(15):1375–83.
Gao H, Li L, Zhang C, Tu J, Geng X, Wang J, et al. Systematic Review with Meta-analysis: Association of Helicobacter pylori Infection with Esophageal Cancer. Gastroenterol Res Pract. 2019;2019:1953497.
doi: 10.1155/2019/1953497
pubmed: 31871444
pmcid: 6913313
Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, et al. Association between Helicobacter pylori and Barrett’s. Esophagus Erosive Esophagitis Gastroesophageal Reflux Symptoms Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc Februar. 2014;12(2):239–45.
Kim JA, Shah PM. Screening and prevention strategies and endoscopic management of early esophageal cancer. Chin Clin. Oncol. 2017;6(5):7–7.
Shaheen NJ, Falk GW, Iyer PG, Clinical Guideline GLBACG. Diagnosis and Management of Barrett’s. Esophagus Off J Am Coll Gastroenterol Acg Januar. 2016;111(1):30–50.
Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518–27.
doi: 10.1016/S1470-2045(12)70112-2
pubmed: 22440112
Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 16. Juli 2013;159(2):77–85.
Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau JM, Esteban JM, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position. Statement Endosc. 2017;49(2):191–8.
Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, u. a. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190(5):562–72; discussion 572–573.
doi: 10.1016/S1072-7515(00)00238-6
pubmed: 10801023
Varghese TK, Hofstetter WL, Rizk NP, Low DE, Darling GE, Watson TJ, et al. The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg. 2013;96(1):346–56.
doi: 10.1016/j.athoracsur.2013.02.069
pubmed: 23752201
Curvers WL, Alvarez Herrero L, Wallace MB, Song WKLM, Ragunath K, Wolfsen HC, et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett’s esophagus. Gastroenterology. 2010;139(4):1106–14.
doi: 10.1053/j.gastro.2010.06.045
pubmed: 20600033
Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;25(11):882–7.
doi: 10.1097/00003072-200011000-00005
pubmed: 11079584
Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449–72.
doi: 10.1136/gut.2010.228254
pubmed: 21705456
Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 25. Dezember 2014;371(26):2499–509.
Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, et al. Treatment outcomes of resected esophageal cancer. Ann Surg Sept. 2002;236(3):376–84. discussion 384–385.
doi: 10.1097/00000658-200209000-00014
Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Cancer Netw Jnccn Februar. 2015;13(2):194–227.
doi: 10.6004/jnccn.2015.0028
Schröder W, Bollschweiler E, Kossow C, Hölscher AH. Preoperative risk analysis—a reliable predictor of postoperative outcome after transthoracic esophagectomy? Langenbecks Arch Surg. 2006;391(5):455–60.
doi: 10.1007/s00423-006-0067-z
pubmed: 16896830
Lagarde SM, Maris AKD, de Castro SMM, Busch ORC, Obertop H, van Lanschot JJB. Evaluation of O‑POSSUM in predicting in-hospital mortality after resection for oesophageal cancer. Br J Surg. 2007;94(12):1521–6.
doi: 10.1002/bjs.5850
pubmed: 17929231
Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, u. a. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. März 2017;20(2):217–25.
SEER*Explorer Application [Internet]. [zitiert 23. August 2021]. Verfügbar unter: https://seer.cancer.gov/explorer/application.html?site=17&data_type=4&graph_type=5&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&series=stage&chk_stage_104=104&chk_stage_105=105&chk_stage_106=106&chk_stage_107=107&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&advopt_display=2
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. Juli 2010;17(7):1721–4.
Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.
doi: 10.1136/gutjnl-2013-305372
pubmed: 24165758
Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57(9):1200–6.
doi: 10.1136/gut.2007.142539
pubmed: 18460553
Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong LM, Dunagan KT, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137(3):815–23.
doi: 10.1053/j.gastro.2009.05.059
pubmed: 19524578
Ngamruengphong S, Wolfsen HC, Wallace MB. Survival of patients with superficial esophageal adenocarcinoma after endoscopic treatment vs surgery. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. November 2013;11(11):1424–1429.e2; quiz e81.
S3-Leitlinie Ösophaguskarzinom. 2018;163.
Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232–48.
doi: 10.3322/caac.21185
pubmed: 23818335
Lagarde SM, Vrouenraets BC, Stassen LPS, van Lanschot JJB. Evidence-based surgical treatment of esophageal cancer: overview of high-quality studies. Ann Thorac Surg. 2010;89(4):1319–26.
doi: 10.1016/j.athoracsur.2009.09.062
pubmed: 20338377
van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, u. a. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 31. Mai 2012;366(22):2074–84.
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, u. a. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 5. Mai 1999;281(17):1623–7.
Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, u. a. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 11. Juni 1992;326(24):1593–8.
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, u. a. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol Off J Am Soc Clin Oncol. 1. April 2005;23(10):2310–7.
Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, et al. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol. 2005;131(1):67–72.
doi: 10.1007/s00432-004-0604-5
pubmed: 15480782
Chang DT, Chapman C, Shen J, Su Z, Koong AC. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. Am J Clin Oncol. 2009;32(4):405–10.
doi: 10.1097/COC.0b013e3181917158
pubmed: 19415029
Ténière P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 1991;173(2):123–30.
pubmed: 1925862
Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.
doi: 10.1016/S1470-2045(15)00553-7
pubmed: 26822397
Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, et al. Cisplatin and 5‑fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol Off J Eur Soc Med Oncol. 2020;31(2):228–35.
doi: 10.1016/j.annonc.2019.10.018
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, u. a. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 1. November 2006;24(31):4991–7.
Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, u. a. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5‑FU) With epirubicin, cisplatin, and PVI 5‑FU in advanced esophagogastric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 15. April 2002;20(8):1996–2004.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet Lond Engl. 28. August. 2021;398(10302):759–71.
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, u. a. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. Juli 2015;18(3):476–84.
Dai Y, Li C, Xie Y, Liu X, Zhang J, Zhou J, u. a. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 30. Oktober 2014;(10):CD005048.